albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-08 and is reviewed periodically as new material appears.
序列层面的改动同时解决了两个问题,即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟,主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库,使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发,属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物,其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代,使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸,进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链,该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用,受体属于 B 类 G 蛋白偶联受体家族,激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞,信号促进葡萄糖依赖性的胰岛素释放,血糖偏低时该作用明显减弱。在胰岛 α 细胞,胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达,相应信号参与食欲调节以及胃排空速率的降低。
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集,这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限,超出标签条件的稳定性仍属开放问题,需要在具体制剂中通过实时与加速试验加以确认。
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估,而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
| Property | Value | Notes |
|---|---|---|
| 分子式 | C187H291N45O59 | 按主链与 C18 二酸侧链计算 |
| 分子量 | 约 4113.6 道尔顿 | 游离碱形式,随反离子略有差异 |
| 外观 | 白色至类白色冻干粉末 | 具吸湿性,需干燥保存 |
| 溶解性 | 微溶于水,易溶于碱性缓冲液 | 溶解性随 pH 升高而改善 |
| 等电点 | 约 5.4 | 影响缓冲液选择与聚集倾向 |
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Across his life, Wolverine has fathered a son Daken and a daughter X-23, and been a mentor to Kitty Pryde and Jubilee. His archenemy is fellow mutant and Weapon X participant Sabretooth, with whom he shares similar abilities. Alternate iterations of the character have included variations in origin, morality, and sexual orientation. The character was co-created by writer Len Wein and Marvel art director John Romita Sr., with his first published appearance written by Wein and drawn by artist Herb Trimpe. After joining the X-Men in 1975, the character was significantly developed by writer Chris Claremont, artist Dave Cockrum, and artist-writer John Byrne. He gained greater prominence as a standalone character when artist Frank Miller collaborated with Claremont on a four-issue eponymous limited series in 1982, which debuted the character's catchphrase: "I'm the best there is at what I do, but what I do best isn't very nice." Since 1988, Wolverine has often been featured in ongoing, self-titled series, while also remaining a member of X-Men-related comics. Major Wolverine stories include "Wounded Wolf" (1986), "Weapon X" (1991), "Enemy of the State" (2004–2005), and "Old Man Logan" (2008–2009). Wolverine quickly emerged as the breakout character of the X-Men, and is among the most popular Marvel Comics characters. His willingness to use deadly force and his brooding loner nature became defining attributes of the many comic book antiheroes that emerged in the aftermath of the Vietnam War.
=== Femarelle Rejuvenate === Femarelle Rejuvenate is intended for women in the perimenopausal stage and focuses on symptoms associated with hormonal fluctuations, including mood changes, tiredness, and changes affecting skin and hair. The formulation contains DT56a together with biotin and riboflavin (vitamin B2).
=== Foe === A foe is a unit of energy equal to 1044 joules (≈9.478×1040 BTU) that was invented by physicist Gerry Brown of Stony Brook University. To measure the staggeringly immense amount of energy produced by a supernova, specialists occasionally use the "foe", an acronym derived from the phrase [ten to the power of] fifty-one ergs, or 1051 ergs. This unit of measure is convenient because a supernova typically releases about one foe of observable energy in a very short period of time (which can be measured in seconds).
Sources: en.wikipedia.org
== Prevention == There are various approaches that are used widely for preventing pressure ulcers. Suggested approaches include modifications to bedding and mattresses, different support systems for taking pressure off of affected areas, airing of surfaces of the body, skin care, nutrition, and organizational modifications (for example, changing the care routines in hospitals or homes where people require extended bedrest). Overall, unbiased clinical studies to determine the effectiveness of these types of interventions and to determine the most effective intervention are needed in order to best prevent pressure ulcers.
== Further reading == Jarvis, Lisa M.; Morrison, Jessica (2015-10-24). "What's nitro cold brew, and why is it so damn delicious?". Chemical & Engineering News. Calderone, Julia; Bartels, Meghan (2016-06-01). "Why Starbucks is pumping nitrogen into its coffee". Business Insider. The Best Coffee For Cold Brew
In DPI formulations the micronized active is then blended with larger (typically 50–200 μm) carrier particles, most commonly α-lactose monohydrate, from which the drug detaches on inhalation. The high surface energy and amorphous content generated by jet milling can cause inhalation powders to cohere or to recrystallize on storage, altering aerosol performance over time. Manufacturers therefore typically condition micronized inhalation actives for example by controlled exposure to humidity or solvent vapour to relax surface disorder before formulation. Carrier-based dry powder inhaler formulations require an API with a stable crystalline structure that can withstand the stress of milling, whereas spray drying can yield amorphous particles with faster dissolution than crystalline micronized forms.
== Etymology == The word hypoglycemia is also spelled hypoglycaemia or hypoglycæmia. The term means 'low blood sugar' from Greek ὑπογλυκαιμία, from ὑπο- hypo- 'under' + γλυκύς glykys 'sweet' + αἷμᾰ haima 'blood'.
Sources: en.wikipedia.org
差别集中在三处:第 8 位残基被非天然氨基酸取代,第 34 位换成精氨酸,第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率,侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。
胰岛素释放需要细胞内环腺苷酸与钙信号升高,同时依赖葡萄糖代谢产生的协同信号。血糖水平较低时协同信号不足,分泌增强有限。这一机制在降糖效果与低血糖风险之间提供了缓冲。
白蛋白结合是主要原因,它减少肾小球滤过并保护分子免受蛋白酶降解。序列修饰带来的酶解抵抗同样不可忽略,二者共同作用。脂肪链的疏水性还会影响组织分布,但其对总半衰期的贡献程度仍在研究之中。
冻融过程中冰晶形成与局部浓度升高会促使肽链发生界面吸附和聚集。聚集不仅降低有效含量,还会改变可见异物与不溶性微粒的计数结果。将溶液分装为单次使用的小体积等份可减少循环次数。